Abstract: A method for identifying a patient with malignant tumor on which the effect of an immune checkpoint inhibitor can be more expected, and agents for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, characterized by prescriptions based on identifying a patient with a malignant tumor on which the effect of an immune checkpoint inhibitor can be more expected, by analyzing evaluation items including combinations such as the PD-1 expression intensity, the percentage of the number of PD-1 expressing cells and the like in Treg cells and CD8+ T cells in tumor tissue or blood.

Abstract: A multilayered resin product includes a resin substrate and a hard coat layer, wherein each side or one side of the resin substrate is coated with the hard coat layer, the hard coat layer includes a cured product of (A) a UV-curable compound and (B) a fatty acid, a fatty acid ester, or a derivative thereof, and the ratio “(Bs)/(As)” of the content (Bs) of the fatty acid, fatty acid ester, or derivative thereof to the content (As) of the cured product of the UV-curable compound in a surface area of the hard coat layer up to a depth of 100 nm is 0.07 to 3.3. The multilayered resin product may be used as a surface-protective multilayered resin product that advantageously prevents adhesion of stains due to adhesion of a sebum film without showing a decrease in the hard coat properties (e.g., scratch resistance and abrasion resistance) and the optical properties (e.g., transmittance and haze).

Abstract: The present invention provides human B lymphoblastoid cell line AC-33, which is novel, and excellent in proliferativity and fusion capability, and works well as the parental line for obtaining a human monoclonal antibody-producing hybridoma. Said hybridoma possesses excellent proliferativity and stable antibody productivity, thus permitting efficient antibody production over a long period.

Abstract: Process for producing plasminostreptin by cultivating a Streptomyces microorganism.